
Sign up to save your podcasts
Or
A drug designed to slow down cognitive decline in Alzheimer’s, Kisunla, has so far been turned down for approval by the EU.
This has led to huge frustration amongst Alzheimer’s experts that hailed the drug as a game-changer.
Joining guest host Anna Daly to discuss is Dr. Laura O’Philbin, Research and Policy Manager at the Alzheimer Society of Ireland, Professor Sean Kennelly, Clinical Director of the Institute of Memory and Cognition in Tallaght University Hospital and listeners who have been personally impacted by the disease.
Image: Eli Lilly
5
33 ratings
A drug designed to slow down cognitive decline in Alzheimer’s, Kisunla, has so far been turned down for approval by the EU.
This has led to huge frustration amongst Alzheimer’s experts that hailed the drug as a game-changer.
Joining guest host Anna Daly to discuss is Dr. Laura O’Philbin, Research and Policy Manager at the Alzheimer Society of Ireland, Professor Sean Kennelly, Clinical Director of the Institute of Memory and Cognition in Tallaght University Hospital and listeners who have been personally impacted by the disease.
Image: Eli Lilly
56 Listeners
84 Listeners
7 Listeners
45 Listeners
0 Listeners
2 Listeners
15 Listeners
32 Listeners
36 Listeners
0 Listeners
0 Listeners
0 Listeners
1 Listeners
0 Listeners
3 Listeners
0 Listeners
2 Listeners
0 Listeners
76 Listeners
38 Listeners
258 Listeners
0 Listeners
26 Listeners
46 Listeners
115 Listeners
8 Listeners
6 Listeners
9 Listeners
2 Listeners
0 Listeners
9 Listeners
0 Listeners
24 Listeners
0 Listeners